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http://dx.doi.org/10.1016/j.ccr.2012.08.004SUMMARYCell polarization is crucial during development and tissue homeostasis and is regulated by conserved
proteins of the Scribble, Crumbs, and Par complexes. In mouse skin tumorigenesis, Par3 deficiency results
in reduced papilloma formation and growth. Par3mediates its tumor-promoting activity through regulation of
growth and survival, since Par3 deletion increases apoptosis and reduces growth in vivo and in vitro. In
contrast, Par3-deficient mice are predisposed to formation of keratoacanthomas, cutaneous tumors thought
to originate from different cellular origin and frequently observed in humans. Par3 expression is reduced in
both mouse and human keratoacanthomas, indicating tumor-suppressive properties of Par3. Our results
identify a dual function of Par3 in skin cancer, with both pro-oncogenic and tumor-suppressive activity
depending on the tumor type.INTRODUCTION
Cell polarity is regulated by sets of polarity proteins including the
Scribble, Par3, and Crumbs polarity complexes, which have
been identified in invertebrates and show conserved functions
in mammals (Asse´mat et al., 2008). The Par3 complex, consist-
ing of partitioning-defective (Par)3, the Ser/Thr kinase atypical
PKC (aPKC), and Par6, has the most ubiquitous function, being
involved, for example, in apico-basal polarity, asymmetric cell
division, and polarization of neuronal and T cells (Macara,
2004). Par3, aPKC, and Par6 can form a ternary complex, but
in certain processes Par3 is excluded from the aPKC-Par6Significance
Although loss of cell polarity is considered a prerequisite for
strating polarity protein function in mammalian tumorigenicity
Par3 polarity protein in cancer. In skin, Par3 acts both as tumo
type involved. Par3 localizes aPKC and Ras signaling compon
tion results in increased formation of Ras-induced keratoacan
ously or as an adverse effect of anticancer drugs. Chemical ca
for keratoacanthoma development relevant for human disease.
Par3 to oncogenic processes.
Candomain through aPKC-mediated phosphorylation (Morais-de-
Sa´ et al., 2010; Horikoshi et al., 2009). Par3 binds multiple pro-
teins including the Rac-GEF Tiam1, thereby coupling Rac
activation to Par polarity signaling. Cross-talk between polarity
complexes and Rho GTPases is necessary to accomplish the
cytoskeletal changes required for cell polarization (Iden and
Collard, 2008).
Loss of polarity is considered a prerequisite for tumor forma-
tion and progression. In D. melanogaster, mutations in genes
of the Scribble complex (Scribble, Dlg, and Lgl) cause loss of
apico-basal polarity and neoplastic outgrowth when mutated
or combined withRasmutations (Bilder, 2004). In human tumors,tumor formation and progression, in vivo evidence demon-
is limited. We show functional consequences of loss of the
r promoter and tumor suppressor, depending on the tumor
ents to cell-cell contacts. Importantly, epidermal Par3 dele-
thoma. This tumor occurs frequently in humans, spontane-
rcinogenesis in Par3-deficient mice provides a useful model
Our data unravel a highly context-dependent contribution of
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Dual Role of Par3 in Skin Tumorigenesisthe expression of polarity proteins is frequently altered though
this seems to be highly context-dependent. Scribble complex
proteins, similar to their tumor-suppressive function in inverte-
brates, show mainly reduced protein levels. In contrast, Par
complex proteins are often upregulated in carcinoma (Nolan
et al., 2008; Huang and Muthuswamy, 2010). Pro-oncogenic
functions have been suggested particularly for aPKCi, because
it seems required for transformation and tumorigenesis of pan-
creatic and lung cancer cells (Murray et al., 2011). In mice,
Par3 deficiency is embryonically lethal (Hirose et al., 2006), and
the function of Par3 during later development and in pathological
situations is unknown.
Oncogenic factors such as UV radiation, chemicals, and path-
ogens aswell as hereditary causes induce avariety of skin tumors
including melanoma, basal cell carcinoma (BCC), squamous cell
carcinoma (SCC), and keratoacanthoma (KA). To elucidate
a potential function of the Par complex in oncogenic processes,
we investigated the consequence of epidermal loss of Par3 on
7,12-dimethylbenz(a)anthracene (DMBA)-initiated and 12-O-
tetradecanoylphorbol-13-acetate (TPA)-promoted skin tumori-
genesis and identified tumor-promoting and -suppressing activ-
ities of Par3 in cutaneous tumors of clinical relevance.
RESULTS
Par3 Deficiency Inhibits Ras-Induced Tumorigenesis
To address a function of Par3 in the skin, we generatedmice with
conditional deletion of Par3 in the epidermis and hair follicle
(K14-Cre+;Par3flox/flox; hereafter Par3 KO). These mice are viable
and reached adulthood comparable to wild-type (WT) litter-
mates. In control skin (K14-Cre+;Par3wt/wt, hereafter WT), Par3
is expressed throughout the interfollicular epidermis and the
hair follicle and atmuch lower levels in the dermis.Par3KO tissue
lacked epithelial Par3 immunoreactivity, and loss of Par3 was
further confirmed in epidermal lysates of newborn and adult
Par3 KO mice (Figure 1A).
To examine if Par3 has a potential function in tumorigenesis,
we applied a two-stage chemical skin carcinogenesis protocol.
Topical treatment with the carcinogen DMBA induced oncogenic
Ras mutations, and subsequent repeated treatments with the
phorbol ester TPA promoted outgrowth of initiated cells resulting
in benign papillomas in WT mice about 7 weeks after initiation.
Interestingly, papilloma formation was delayed by about 3 weeks
in Par3 KO mice (Figure 1B), and tumor multiplicity was strongly
reduced (Figures 1C and 1E; Table S1 available online). More-
over, tumors that did form grew slower in the absence of Par3
(Figure 1D), indicating that Par3 promotes Ras-induced tumor
formation and growth. Typical papillomas in WT mice showed
exophytic growth of squamous cells (Figure 1F). To prepare
tissue lysates, we dissected from same mice both normal skin
and tumors and repeated this for multiple WT and Par3 KO litter-
mates. The analysis of Par3 and aPKC expression in nontumor
and tumor tissue lysates revealed robust levels of Par3 and
aPKC in WT tumors, whereas Par3 protein was undetectable in
Par3 KO skin and tumors (Figure 1G). Together, these functional
and biochemical data suggest a tumor-promoting function of
Par3 in Ras-induced papillomas.
To address the mechanism of reduced tumor formation and
growth in Par3 KO mice, we tested the involvement of Par3 in390 Cancer Cell 22, 389–403, September 11, 2012 ª2012 Elsevier Inepidermal proliferation and apoptosis in response to DMBA/
TPA treatment of the skin. After single DMBA and subsequent
dual TPA treatment, as measured by BrdU incorporation, prolif-
eration was significantly reduced in Par3 KO compared to WT
epidermis (Figure 2A). Furthermore, Par3-deficient epidermis
showed a significant increase in cells positive for cleaved cas-
pase-3, which identifies apoptosis (Figure 2A), normally a rare
event in skin. We isolated skin keratinocytes from mice with
loxP-flanked Exon3 of Par3 (Hirose et al., 2006) to further
address a function of Par3 in cell survival and proliferation.
In keratinocytes, the 180 kDa splice variant of Par3 shows
highest expression, and self-excising Cre recombinase effi-
ciently deleted Par3 (Figure 2B). We expressed oncogenic
Ras (RasV12) in cells (Figure 2C) and studied the role of Par3 in
Ras-induced resistance to contact-mediated growth inhibition.
Upon calcium switch (elevation from 20 mM Ca2+, termed low
calcium [LC], to 2 mM Ca2+, termed normal calcium [NC]), which
induces cadherin-mediated intercellular adhesion, RasV12
enabled keratinocytes continue to grow despite prolonged incu-
bation at NC. In contrast, Par3-deficient cells showed attenuated
growth (Figures 2D and 2E), suggesting that Par3 is required for
Ras signaling to overcome differentiation-induced cell cycle
arrest. This was not due to differential expression of major adhe-
rens junction (AJ) components because loss of Par3 did not
affect the moderate Ras-mediated downregulation of E-cad-
herin and other AJ-associated proteins tested (Figure S2H). In
addition, Par3-deficiency reduced the ability of RasV12 cells
to form colonies in matrigel (Figure 2E) or soft-agar (data not
shown), further supporting a growth-promoting function of Par3.
We further investigated whether Par3 is involved in activation
of the phosphatidylinositol-3 kinase (PI3K)/Akt and MEK/ERK
pathways, main modules mediating cell survival, proliferation,
and apoptotic resistance in Ras-mediated skin tumorigenesis
(Kern et al., 2011). Par3-deficient keratinocytes indeed exhibit
consistently reduced ERK activation upon Ras expression and/
or TPA treatment (Figures 2F and 2G) and reduced Akt activation
upon Ras expression compared to WT cells (Figure S2B). More-
over, as in carcinogen-exposed skin, apoptosis was increased in
starved, EGF-, or TPA-treated Par3 KO keratinocytes as evi-
denced by caspase-3 and Parp1-cleavage (Figure 2H). Other
stimuli such as heat shock and growth factor deprivation simi-
larly induced a stronger apoptotic response in Par3 KO than in
WT cells (Figure S2D; data not shown). Increased Bax confor-
mational change and caspase-9 processing in Par3 KO cells
indicated activation of the intrinsic, mitochondria-dependent
apoptotic pathway in the observed apoptotic phenotype (Fig-
ures 2I, S2E, and S2F). Finally, cyclin D1 levels in Par3 KO cells
were lower than in WT cells (Figure S2C). This difference was
further increased upon expression of oncogenic Ras, known to
induce cyclin D1 expression (Filmus et al., 1994). Together, these
results indicate that Par3 is required for Ras-induced tumor
growth and promotes ERK- and Akt-mediated growth and sur-
vival signals that counterbalance apoptotic signaling.
Par3 Interacts with and Localizes aPKC in Cultured
Keratinocytes
Because Par3 has been shown to act together with aPKC
in several cellular systems, we analyzed the subcellular locali-
zation of Par3 and aPKC in keratinocytes. At NC, Par3 wasc.
Figure 1. Mice with Epidermal Par3 Deletion Show Reduced Ras-Mediated Tumorigenesis
(A) Western blot against Par3 and a-tubulin from epidermal lysates (left: epidermis from newborns; right: epidermis from 8 weeks old mice) and immunohisto-
chemical Par3 staining of adult K14-Cre+;Par3wt/wt (WT) or K14-Cre+;Par3flox/flox (Par3 KO) mice (right). Scale bars, 100 mm.
(B) Tumor incidence, indicated by percentage of tumor-bearing mice, in WT and epidermal Par3 KO mice. n(WT) = 25, n(KO) = 27.
(C) Average number of tumors per mouse in WT and epidermal Par3 KO mice (mean ± SEM).
(D) Tumor volume (length 3 width 3 height) in WT mice and epidermal Par3 KO mice. Representative data are shown for 14.5 weeks post-DMBA.
(E) Representative photographs of TPA-treated WT and epidermal Par3 KO mice 10 and 14 weeks after tumor initiation.
(F) Histologic sections of papillary hyperplasia and papilloma in WT mice, H&E. Scale bars, 500 mm.
(G) Western blot analysis of Par3 and aPKC expression in lysates of WT and Par3 KO skin and tumors. Vertical white lines indicate that lanes were removed
between the samples shown. ns, normal skin; t, tumor tissue; a-tub, a-tubulin.
See also Figure S1.
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Figure 2. Reduced Proliferation and Cell Survival and Increased Apoptosis upon Epidermal Par3 Deletion
(A) Back-skin of mice was treated once with DMBA and twice with TPA with a 3 day interval. Proliferation and apoptosis 24 hr after last treatment was quantified
based on immunohistochemical analyses (mean ± SEM) (see Experimental Procedures for details).
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Dual Role of Par3 in Skin Tumorigenesispredominantly found at ZO-1-positive cell-cell contacts of WT
cells, whereas in Par3 KO cells it was not (Figure 3A). The
ZO-1 pattern was discontinuous in Par3 KO cells in early phases
of junction formation indicating impaired tight junction matura-
tion upon loss of Par3 (6 hr NC; Figure 3A), which could be
restored by myc-PAR3 expression (Figure S2A). In contrast,
48 hr after calcium switch ZO-1 distribution was comparable to
WT cells (data not shown), indicating a temporary requirement
of Par3 in initial steps of tight junction (TJ) formation as described
for other epithelial cell types (Chen and Macara, 2005). Immuno-
staining revealed colocalization of Par3 and aPKC at keratino-
cyte TJs (Figure 3B), and co-immunoprecipitation revealed bind-
ing of both endogenous proteins inWT keratinocytes (Figure 3C),
indicating the presence of a functional Par3-aPKC complex. In
WT cells, we found aPKC localization at newly formed cell-cell
contacts (30 min and 2 hr at NC) and at established intercellular
junction of multilayered keratinocytes (3 days at NC on perme-
able supports) (Figure 3D). In Par3 KO cells however, aPKC
showed a diffuse cytoplasmic distribution and was absent at
cell-cell contact sites, both shortly after calcium switch and in
multilayers with established TJs (Figure 3D). As total aPKC levels
are unaffected by Par3 deletion (Figure 3C), our data suggest
that Par3 is required for proper aPKC localization to intercellular
contacts in cultured keratinocytes. Interestingly, similar to myc-
PAR3, expression of membrane-targeted aPKC (aPKC-CAAX)
could restore active ERK levels in Par3 KO keratinocytes after
starvation or when expressing RasV12 combined with TPA stim-
ulation (Figures 3E and 3F). Furthermore, similar to Par3 deletion,
siRNA-mediated depletion of aPKC impaired TPA-induced ERK
activation (Figure S3A) and resulted in increased apoptosis (Fig-
ure S3B), indicating that aPKC likely contributes to Par3-depen-
dent ERK stimulation and survival.
Altered Localization of Ras-MAPK Pathway
Components upon Loss of Par3
To assess how Par3 dysfunction impacts survival and growth
signaling, we analyzed the subcellular localization of crucial
components of the Ras signaling pathway in control and Par3-
deficient epidermis, papillomas, and keratinocytes. Interestingly,
endogenous Ras and its GEF Sos2 localized to cell-cell contacts
of control epidermis and papilloma tissue in a pattern similar to
that of Par3 (Figure 4A, top). This specific localization, however,
was strongly diminished in Par3 KO tissue (Figure 4A, bottom),
suggesting that Par3 mediates the localization of Ras pathway(B) Western blot of cultured keratinocytes upon Cre-mediated Par3 deletion. T
keratinocytes (WT: Par3fl/fl, KO: Par3fl/fl + self-excising Cre). Numbers indicate th
(C) Western blot of transduced oncogenic Ras (RasV12) in WT and Par3 KO kera
(D) Phase-contrast micrographs of WT and Par3 KO keratinocytes either untrea
differentiating (normal Ca2+, bottom) conditions. Scale bars, 20 mm.
(E) Proliferation and colony formation induced by oncogenic Ras. Cell proliferati
suspensions of RasV12-infected WT and Par3 KO keratinocytes into matrigel an
(F) Western blot analysis of total cell lysates to detect ERK activation in WT an
keratinocytes were infected with oncogenic Ras and/or treated with 0.68 mM TP
(G) Quantification of F, ERK activation upon loss of Par3 in starved, Ras-express
(H) WT and Par3 KO cells were cultured at NC for 36 hr, serum-starved and treated
ERK pathway activity by pMEK and pERK levels. Asterisk: full-length Parp1; arro
(I) Quantification of apoptosis markers upon starvation (nR 3) (mean ± SEM). Rep
**p < 0.01.
See also Figure S2.
Cancomponents to intercellular adhesions. In primary keratinocytes,
endogenous Ras and Par3 indeed colocalized at cell-cell con-
tacts (Figure 4B) and both exogenous oncogenic RasV12 and
endogenous Sos2 colocalized with ZO-1 (Figures 4B and 4C),
indicating that they associate with TJs. RasV12 further codistrib-
uted with Par3 at cell-cell contacts in WT keratinocytes (Fig-
ure 5A, top), whereas this localization was diminished in Par3
KO keratinocytes (Figure 5A, middle). Importantly, RasV12 local-
ization to intercellular contacts could be restored by expression
of exogenous human myc-PAR3 in Par3 KO cells (Figure 5A,
bottom), suggesting that Par3 mediates localization of active
Ras to these sites. In line with the in vivo data (Figure 4A) also
Sos2 displayed Par3-dependent cell-cell contact localization
as evident by loss of Sos2 from these sites in Par3 KO keratino-
cytes cultured at NC (Figure 5B). Finally, next to cytoplasmic and
nuclear pools we observed the active form of the downstream
effector ERK1/2 (pERK1/2) at cell-cell contacts in WT cells (Fig-
ure 5C), colocalizing with aPKC (Figure 5D). Similar to Ras and
Sos2, pERK1/2 was not found at intercellular contacts of Par3
KO cells (Figures 5C and 5D, right). Ras, Sos2, MEK, and ERK
protein levels were unaffected by loss of Par3 in keratinocytes
(Figure 5E), excluding that Par3 regulates the expression of these
proteins. Together, the above data suggest that junctional Par3
mediates localization of Ras pathway components and thereby
helps to assemble a functional, signaling-competent platform
at intercellular contacts that efficiently stimulates growth and
survival signaling in papillomagenesis.
Increased Formation of Keratoacanthoma in
Par3-Deficient Mice
To examine if Par3 is important for the progression of papillomas
to SCCs,micewere inspected thoroughly during the experiment.
While papillomas, the predominant tumors of WT mice, showed
clear exophytic growth with a narrow stem connecting tumor
mass and skin (Figures 1F and S1A), Par3 KO mice often
developed tumors with initially glossy surface that rapidly grew
inward (Figures 6A and 6B). This caused experiment termination
22 weeks postinitiation as tumor sizes reached >1 cm. At dissec-
tion we noticed deep protrusion of tumors into the dermis and
presence of strong vascularization at the base. These tumors
were histologically identified as keratoacanthoma (KA), a tumor
rarely observed in mice but common in human, with typical
crater-like morphology, broad tumor base and a keratin-filled
center (Figures 6B, S1D, S1H, and S1I). Histopathologicalhe 180kDa band shown reflects the dominantly expressed splice variant in
e relative Par3 expression after normalization to loading control a-tubulin.
tinocytes. Rac served as loading control.
ted (left) or upon expression of RasV12 (right) at growth (low Ca2+, top) and
on on culture plates (left) and colony formation in 3D upon seeding single cell
d incubation for 10 days at NC (right) was assessed (mean ± SD).
d Par3 KO cells (bottom: longer exposure of top pERK blot). Serum-starved
A for indicated time points.
ing and TPA-treated cells (nR 4) (mean ± SEM).
with TPA or EGF. Apoptosis was indicated by caspase-3 and Parp1 cleavage,
w: cleaved Parp1 fragment.
resentative western blots for caspase-9 are provided in Figure S2E. *p < 0.05;
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Figure 3. Par3 Interacts with aPKC and Mediates Cell-Cell Contact Localization of aPKC in Keratinocytes
(A) Endogenous Par3 and ZO-1 immunostaining 6 hr after calcium switch to NC. Continuous, thin lines of ZO-1 immunoreactivity indicate matured tight junctions.
Scale bar, 10 mm.
(B) Co-immunostaining of aPKC and Par3 in WT keratinocytes cultured for 24 hr at NC. Scale bar, 10 mm.
(C) Co-immunoprecipitation of endogenous Par3 and aPKC in WT keratinocytes 6 hr after Ca2+ switch (see Supplemental Experimental Procedures for details).
Vertical white lines indicate that lanes were removed between the samples shown.
(D) Immunostaining against aPKC and ZO-1 in WT and Par3 KO keratinocytes. Various time points after calcium switch were analyzed as indicated on top. Scale
bars, 10 mm.
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Dual Role of Par3 in Skin Tumorigenesisanalyses confirmed that at termination Par3KOmice had formed
6.63 KAs per mouse (91% of mice KA-positive; Table S1),
whereas in WT mice only 0.53 KAs per mouse were detected
(27% of WT mice KA-positive; Table S1), which were too small
to be macroscopically classified as such. Formation of SCCs
was in total rare at week 22 but Par3 KO mice appeared not to
be prone to SCC formation. WT mice had slightly increased
SCC formation (0.4 SCCs per mouse, 20% of WT mice SCC-
positive; Table S1) compared to Par3 KO mice (0.18 SCCs per
mouse, 18% of KO mice SCC-positive; Table S1). Of note, all
tumors tested were positive for Ras codon 61 mutations (Fig-
ure S4A) described to be induced by DMBA (Finch et al.,
1996), indicating that KAs were also induced by oncogenic Ras
signaling. Lack of Par3 expression was confirmed in all tested
Par3 KO-derived tumors (data not shown), excluding the possi-
bility that KAs developed from rare cells that had escaped Cre-
mediated Par3 deletion. The remarkably increased incidence
and accelerated appearance of KAs in Par3 KO mice (Figures
6C and 6D; Table S1) contrasted the reduced papilloma forma-
tion in these mice (Figures 1B, 1C, and 6D; Table S1), indicating
a dual function of Par3 in development of skin tumors dependent
on the tumor type.
To address further the molecular functions of Par3 in the skin
and the different skin tumors, we explored the subcellular local-
ization of Par3 and aPKC in skin tissue. Par3 was robustly ex-
pressed in epidermis and papilloma tissue, where it localized
to sites of cell-cell contacts (Figure 6E, top), but was lost in the
few KAs of WTmice (Figure 6E, top). Similar to cultured keratino-
cytes (Figure 3D), we found a requirement of Par3 for junctional
localization of aPKC in vivo, as aPKC was strikingly mislocalized
to the cytoplasm in Par3-deficient epidermis and tumors as well
as in the rare WT KAs that displayed reduced Par3 levels (Fig-
ure 6E, middle and bottom). Instead, ZO-1 showed normal TJ
distribution in WT and Par3 KO epidermis and appeared corti-
cally distributed but scattered both in WT papilloma and Par3
KO KAs (Figure S4D), suggesting Par3-independent ZO-1 local-
ization in this context. Since KAs also develop in humans, we
further investigated possible similarities between Ras-induced
mouse tumors and patient-derived KAs. Quantitative analyses
of sections of non-diseased human skin and 10 KA tumors re-
vealed that PAR3 was clearly detectable in basal and suprabasal
layers of healthy epidermis and in epidermis adjacent to tumors,
partially colocalizing with E-CADHERIN, ZO-1 and aPKC (Fig-
ure S4C). However, its expression was significantly reduced in
the tumor epithelium of KAs (Figures 6G, 6H, and S4B), similarly
as found in murine WT KAs. In contrast, analysis of human SCCs
did not reveal significantly reduced PAR3 expression (Figure 6H,
bottom panel; Figure S4B, right panel), in line with the lack of
significant alterations of SCC incidence in Par3 KO mice (Table
S1). From these data we conclude that Par3 expression and
localization differs in papillomas and KAs, consistent with the
differential tumor outcome in mice with Par3 deletion (Figures 1
and 6; Table S1). Analysis of keratinocytes cultured at LC versus(E) Expression of myc-hPAR3 and of membrane-targeted aPKC (aPKC-CAAX) in
cultured at NC and treated with TPA.
(F) Quantification of ERK activity inWT and KOPar3KO keratinocytes transfected
expression of RasV12 and subsequent TPA treatment (right) (n = 3). Mean ± SEM
See also Figure S3.
CanNC indicated that depending on the cellular context and
presence of cell-cell contacts Par3 is differentially required for
MAPK signaling (Figure S3D). We therefore assessed if a
differential activity of crucial MAPK components could be con-
firmed in tumor tissues. Interestingly, we observed abnormally
high levels of phosphorylated active CRaf in a distinct vesicular
pattern in basal layers of Par3 KO epidermis as well as Par3-
deficient KAs (Figure 7A, bottom). In contrast, in WT epidermis
this active CRaf was moderately detected at cell-cell contacts
of the suprabasal layers, in few vesicular structures in the
basal layer and was only very weakly present in WT papilloma
tissue (Figure 7A, top). These data implicate Par3 in CRaf acti-
vation and/or localization in the context of KA formation. The
abundance of active CRaf in intracellular vesicles has been re-
ported previously (Rizzo et al., 2001) and could be recapitulated
in vitro in Par3 KO but not WT keratinocytes cultured at LC (Fig-
ure 7B), suggesting that in the absence of profound intercellular
adhesions cytoplasmic Par3 serves to restrict CRAF activity.
Together, the above data indicate that the tumor-suppressive
function of Par3 in KA formation involves regulation of CRaf and
illustrate that polarity proteins contribute to clinically relevant
pathologies.
DISCUSSION
Our functional tumorigenicity studies reveal a hitherto unknown
role of the Par3 polarity protein in mammalian cancer, i.e., a
tumor-promoting function in papilloma formation and tumor-
suppressive activity in KA formation. Previously, polarity proteins
of the Scribble complex have been implicated in tumor suppres-
sion in D.melanogaster, in D.rerio and recently in mice (Bilder,
2004; Reischauer et al., 2009; Zhan et al., 2008; Pearson et al.,
2011). Similarly, Par4/LKB1 shows tumor-suppressive activity
(Vaahtomeri and Ma¨kela¨, 2011), and loss of Par4/LKB1 associ-
ated with impaired epithelial integrity synergizes with oncogenic
c-myc induced mammary tumorigenesis (Partanen et al., 2012).
In the DMBA/TPA tumor model involving Ras mutations, we
found that Par3 can serve either as a tumor promoter in papil-
loma formation or a tumor suppressor in KA formation. Par3-
deficient mice did not develop spontaneous skin tumors,
indicating that Par3 dysfunction in mice alone is not sufficient
to drive tumorigenesis. Malignant transformation of papillomas
by local invasion into the stroma was observed in 45% of the
relatively small tumors found in Par3 KO mice and in 33% of
the abundant larger tumors of WT mice (Table S1), suggesting
that loss of Par3 promotes Ras-mediated metastasis of tumor
cells as found in Drosophila (Pagliarini and Xu, 2003). Similarly,
local invasion by KAs was exclusively observed in Par3 KO
mice (36%; Table S1) although we cannot exclude that this is
the result of the earlier onset of KAs in these mice.
Isolated epidermal keratinocytes appear to recapitulate well
what is occurring during papillomagenesis. In the absence
of Par3, both carcinogen-exposed epidermis and culturedPar3 KO keratinocytes to restore ERK activity. RasV12-expressing cells were
with control plasmid, myc-hPAR3 or aPKC-CAAX, either untreated (left) or upon
; **p < 0.01; ***p < 0.001.
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Figure 4. The Localization of Ras and the RasGEF Sos2 to Cell-Cell Contacts Is Par3-Dependent
(A) Immunostaining of Ras and the Ras-GEF Sos2 in murine epidermis adjacent (left) to papillomas (right) in WT (top) and Par3 KO (bottom) tissues. Scale
bars, 20 mm.
(B) Co-immunostaining of endogenous Par3 and Ras, and of oncogenic Ras (HA-RasV12, stained with HA-tag antibodies) with the endogenous, TJ-associated
protein ZO-1 in WT keratinocytes. Scale bars, 20 mm.
(C) Co-immunostaining of the endogenous Ras-GEF Sos2 with ZO-1 in WT keratinocytes 48 hr after switch to NC. Scale bars, 20 mm.
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Dual Role of Par3 in Skin Tumorigenesiskeratinocytes show reduced proliferative responses and higher
apoptotic sensitivity (Figure 2). Par3 likely promotes Ras-
induced ERK- and Akt-mediated cell growth and apoptotic resis-
tance giving rise to papillomas. To date, no direct molecular link
between Par3 and Ras signaling has been reported. Recently,
direct binding of Par3 to PI3K, PTEN and phosphoinositides
and a positive feedback of the Par3 complex to PI3K has been396 Cancer Cell 22, 389–403, September 11, 2012 ª2012 Elsevier Inpostulated in the context of axon formation and establishment
of plasma membrane polarity (Itoh et al., 2010; Yoshimura
et al., 2006; Cain and Ridley, 2009). Our findings of reduced
Akt activity upon loss of Par3 in keratinocytes suggest that
such interactions also sustain survival signals in skin tumorigen-
esis. We further provide evidence that loss of Par3, concomitant
with reduced survival signaling, results in activation of thec.
Figure 5. Mislocalization of Ras Pathway Components upon Loss of Par3 in Epidermis, Skin Tumors, and Keratinocytes
(A) Immunofluorescent co-staining of RasV12, stained with HA-tag antibodies, and Par3 in WT keratinocytes (top), in Par3 KO cells (middle), and in Par3 KO
keratinocytes expressing myc-PAR3 (bottom). All cells were cultured at NC. Scale bars, 20 mm.
(B) Immunofluorescent staining of Sos2 to depict its localization in WT and Par3 KO keratinocytes. Scale bars, 20 mm.
(C) Immunofluorescent staining of phosphorylated ERK1/2 in WT (left) and Par3 KO (right) keratinocytes to detect sites of high ERK activity. Scale bars, 20 mm.
(D) Immunofluorescent staining of aPKC and active ERK (pERK1/2) to depict colocalization in WT and Par3 KO keratinocytes expressing RasV12 and cultured
at NC. Scale bars, 20 mm.
(E) Western blot analysis of Sos2, MEK, ERK2, and Ras and Rac protein levels in WT and Par3 KO keratinocytes.
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Dual Role of Par3 in Skin Tumorigenesisintrinsic mitochondria-dependent apoptotic pathway (Figures 2I,
S2E, and S2F), which has earlier been implicated in balancing
skin tumor growth in the DMBA/TPA tumor model (Cho et al.,
2001) and mediating UV-induced cell death in human keratino-
cytes (Van Laethem et al., 2004).
We and others have shown that Par3 can cross-talk to Rho
GTPase signaling through interaction with the Rac-GEF Tiam1.
Tiam1 and Rac collaborate with the Par3-aPKC complex to
regulate TJ biogenesis and persistent migration of keratinocytes
(Iden and Collard, 2008). Similar to Tiam1-depleted cells, Par3
KO keratinocytes are impaired in scratch-induced wound clo-
sure (Figure S2G). Interestingly, deletion of Tiam1 or Rac1 also
suppresses Ras-induced papilloma formation (Malliri et al.,
2002; Wang et al., 2010), suggesting that Par3 and Tiam1/
Rac1 function is coupled not only during cell polarization but
also in tumorigenic events downstream of Ras. Considering
the striking resemblance between papilloma phenotypes upon
deletion of Tiam1, Rac1 or Par3, and our previous findings thatCanTiam1/Rac regulates the Par3 complex in polarizing keratino-
cytes (Pegtel et al., 2007) we speculate that Par3 acts at the level
of Tiam1/Rac in papillomagenesis. Of note, the increased KA
incidence in Par3 KO mice has not been observed in Tiam1-
and Rac1-deficient mice, indicating that the tumor-suppressive
effect of Par3 on KA formation is not coupled to Tiam1/Rac
signaling. Moreover, in contrast to increased SCC formation in
Tiam1-KOmice (Malliri et al., 2002), we could not detect a signif-
icant contribution of Par3 expression on SCC formation
(Table S1). A recent report implicates the RAS/RAF/MAPK axis
in formation of human SCC (Reuter et al., 2009). Due to the
rapidly growing KAs, which appear much earlier than SCCs,
animals needed to be sacrificed before profound SCC onset,
preventing a statistically validated conclusion on the function
of Par3 in SCC formation. Hence, considering the different
kinetics of SCC and KA formation, we cannot exclude that
SCC initiation is altered upon loss of Par3. However, we did
not detect significant differences in the expression of PAR3 incer Cell 22, 389–403, September 11, 2012 ª2012 Elsevier Inc. 397
Figure 6. Par3 cKO Mice Develop Keratoacanthomas
(A) Representative photograph of keratoacanthomas in Par3 KO mice 21 weeks post-DMBA.
(B) Representative H&E staining of KA cross-section. Scale bar, 1 mm.
(C) KA incidence based on macroscopic analysis of WT and Par3 KO mice. For histologic analyses, see Table S1.
(D) Number of papillomas versus KAs per mouse based on macroscopic analysis at week 13.5 post-DMBA. For histologic analyses, see Table S1.
(E) Par3 and aPKC immunostaining in cryosections of mouse epidermis, papilloma and KA. b4 integrin signal reflects the epidermal-dermal border. Scale bars,
20 mm. T, tumor; S, stroma.
(F) Quantification of Par3 protein expression in KAs of WT mice and epidermis adjacent to the tumors.
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Figure 7. Altered Localization and Activity
of CRaf in Par3-Deficient Epidermis and
Skin Tumors
(A) Immunofluorescent staining of phosphorylated
CRaf, reflecting the active form of CRaf in WT
and Par3 KO epidermis and tumor tissues. Scale
bars, 20 mm.
(B) Immunofluorescent staining of phosphorylated
CRaf in WT and Par3 KO keratinocytes cultured at
LC conditions. Scale bars, 20 mm.
(C) Model representing experimental skin tumori-
genesis in WT and Par3 KO mice. While papil-
lomas likely arise mostly from suprabasal layers of
the interfollicular epidermis, KAs are considered to
originate from the hair follicle (Perez-Losada and
Balmain, 2003). In WT epidermis and papillomas,
Par3 and aPKC localize to intercellular adhesions.
In the absence of Par3, papilloma formation and
growth is reduced, which correlates with mis-
localization of aPKC and components of the Ras
pathway, impaired proliferation and survival sig-
naling, and increased apoptosis, indicating tumor-
promoting functions of Par3. In contrast, Par3 KO
mice develop significantly more KAs, suggesting
a tumor-suppressive function of Par3 in hair
follicular cells giving rise to KAs. This highlights
opposing functions of Par3 in tumorigenesis de-
pending on the tumor origin.
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and S4E), suggesting that the impact of Par3 expression on
SCC formation is different as compared to KA formation. This
leaves the possibility that Par3 function can be replaced by as
yet unknown proteins in SCC but not KA formation.
The origin and development of KAs are not well understood.
Proliferating cells of the basal and suprabasal layers of the inter-
follicular epidermis and the subsets of cells in the hair follicle
each face a different microenvironment, which may eventually
define the tumor outcome in pathologic conditions. Predominant
expression of oncogenic Ras in differentiated interfollicular ker-
atinocytes and subsequent tumor promotion induces papillomas
(Bailleul et al., 1990; Greenhalgh et al., 1993; Owens and Watt,
2003). In contrast, expression of Ras in basal cells of the hair
follicle results in the formation of KAs and SCCs that are inde-
pendent of exogenous tumor promotion (Brown et al., 1998),(G) PAR3 expression in human epidermis and KA (paraffin sections). Colored boxes in overview indicate ins
bar, 100 mm.
(H) Quantification of PAR3 expression in human KAs and SCCs compared to adjacent epidermis (cryo
Figure S4B. Mean ± SEM; **p < 0.02; ***p < 0.001.
See also Figure S4 and Table S1.
Cancer Cell 22, 389–403, Seindicating that the cell of KA origin resides
in the hair follicle and shows little dif-
ferentiation (Perez-Losada and Balmain,
2003). Par3 is expressed throughout the
interfollicular epidermis and hair follicle
but may act at different intracellular sites
in cells giving rise to papillomas and
KAs, respectively. Such cell type specific
functions could explain the opposingtumor outcome observed in Par3 KO mice (Figure 6D). While
the formation of papillomas correlates with robust Par3 expres-
sion and localization to cell-cell contacts (Figures 1G and 6E),
Par3 is strongly reduced in KAs and is rarely found at intercellular
contact sites (Figure 6E). The differential outcome of Par3 defi-
ciency on papilloma versus KA formation in vivo intriguingly
parallels our observation that Par3 promotes growth and survival
signaling in vitro only when cell-cell contacts are established. At
LC conditions when Par3 is not enriched at cellular junctions it
does not stimulate ERK, as Par3 KO cells at these conditions
show ERK activity equal to WT cells (Figure S3A). This suggests
that junctional, but not cytoplasmic Par3, promotes cell survival
and growth signaling, possibly by recruiting other proteins to
intercellular adhesions. Indeed, we found that several compo-
nents of the Ras-MAPK signaling pathway, including Ras, its
GEF Sos2, and its effector pERK, localize to cell-cell contactsets of KA (black) and epidermal (red) tissue. Scale
sections). Related examples of micrographs see
ptember 11, 2012 ª2012 Elsevier Inc. 399
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ERK activation in cells with established cell-cell contacts. Inter-
estingly, in human intestinal epithelial cells cortical active
ERK1/2 has been recently associated with a stronger EGF-
induced ERK activation as compared to cytoplasmic ERK in
under-differentiated cells (Basuroy et al., 2006; Aggarwal et al.,
2011). Moreover, we found that Par3 associates with aPKC in
keratinocytes and observed Par3-dependent localization of
aPKC to intercellular contacts both in vitro and in vivo. Impor-
tantly, in Drosophila, cortical aPKC induces neuroblast over-
growth, whereas cytoplasmic aPKCi is associated with poor
prognosis in human ovarian and breast cancer (Grifoni et al.,
2007; Kojima et al., 2008). aPKCi also mediates tumor cell
growth, transformation and invasion in vitro and in experimental
Ras-induced lung tumorigenesis likely by stimulating ERK
signaling (Regala et al., 2009). Interestingly, ERK activity in
Par3 KO keratinocytes can be efficiently blocked by aurothioma-
late (ATM) (Figure S3C), a small molecule inhibitor of the aPKC/
Par6 interaction previously demonstrated to block oncogenic
functions of aPKC in lung cancer (Erdogan et al., 2006; Stal-
lings-Mann et al., 2006), indicating that in the absence of Par3
cytoplasmic aPKC can mediate ERK activity via interaction
with Par6. Together, these data suggest that junctional aPKC
contributes to Par3- and Ras-mediated growth and survival
during papilloma formation, whereas increased KA formation
as a result of loss of Par3 may involve oncogenic activities of
cytoplasmic aPKC, likely in complex with Par6.
The Ras-based skin tumor model combined with loss of Par3
presented in this study provides a robust tool to study keratoa-
canthoma formation. Preclinical and clinical studies testing
inhibitors of mutant BRaf to restrict metastatic growth of solid
tumors recently provided evidence that human KAs also result
from deregulated Ras signaling: 15%–31% of patients treated
with the BRaf inhibitor vemurafenib (PLX4032, Roche, and Plex-
xikon) develop KAs or SCCs as adverse effect (Flaherty et al.,
2010; Chapman et al., 2011). The HRas codon 61 mutation has
recently, among other Ras mutations, been confirmed in those
drug-promoted KAs harboring WT BRaf alleles (Oberholzer
et al., 2012; Su et al., 2012). Moreover, in the DMBA/TPA mouse
tumor model, which similarly induces HRas codon 61 mutations,
vemurafenib treatment accelerated the growth of Ras-contain-
ing lesions accompanied by increased MAPK activity (Su et al.,
2012), confirming that verumafenib indeed activates growth
signaling in Rasmutant cells in vivo. BRaf inhibitors likely induce
the formation of Raf dimers that leads to paradoxic CRaf activa-
tion and consequently MAPK pathway hyperactivation (Poulika-
kos et al., 2010; Hatzivassiliou et al., 2010; Heidorn et al., 2010).
The observation of reduced Par3 expression in both mouse and
human KAs (Figures 6E, 6F, 6H, and S4B) and of CRaf hyper-
activation in Par3-deficient KAs (Figure 7A) therefore suggests a
common mechanism of KA formation in human and mice involv-
ing Ras mutation and Par3 dysfunction.
In conclusion, we identified a tumor type-dependent function
of Par3 in Ras-mediated skin cancer, with (pro)oncogenic and
tumor-suppressive activity during papilloma and KA forma-
tion, respectively (Figure 7C). Our data underscore an important
context-dependent role of polarity proteins inmammalian tumor-
igenesis and underlying signaling pathways. Our data further
suggest that polarity protein dysfunction may differentially affect400 Cancer Cell 22, 389–403, September 11, 2012 ª2012 Elsevier Inthe tumor outcome in other tissues depending on the cellular
context. In addition, we present a mouse tumor model of KA
formation that recapitulates a human skin cancer of increasing
clinical relevance.
EXPERIMENTAL PROCEDURES
Epidermal Par3 Deletion
To delete Par3 specifically in the epidermis and hair follicle, mice with a condi-
tional Par3 allele (Hirose et al., 2006) were crossed with K14-Cre(neo)
(Huelsken et al., 2001) mice. For further details see Supplemental Information.
All experiments involving animals in this study were reviewed and approved by
the Animal Experiments and Ethics Committee (DEC) of the Netherlands
Cancer Institute and conformed the regulatory standards of the Dutch Act
on Use of Laboratory animals.
Skin Tumorigenesis Experiments
Two independent DMBA/TPA-mediated two-stage chemical skin carcinogen-
esis experiments were performed as previously described (Malliri et al., 2002).
25 WT (K14-Cre+;Par3wt/wt) and 27 Par3 cKO (K14-Cre+;Par3flox/flox) mice of
mixed genetic background have been used initially, and a repeat experiment
comprised 17 WT and 11 Par3 cKO mice of FVB background (F8). Results
were essentially the same, and representative data are shown. Mice were
examined twice a week, and tumor numbers and sizes were measured. At
termination, normal skin, tumor tissue, and other organs were snap-frozen
or fixed for further analyses.
Tissue Processing, Histology, and Immunohistochemistry
Hematoxylin and eosin (H&E) staining and immunohistochemistry of normal
skin and skin tumors were performed on formalin- or EAF-fixed 4 mm paraffin
sections or 8 mm cryosections. For biochemical analysis, normal skin and
tumor tissue was minced, collected in a tube and supplemented with radioim-
munoprecipitation assay buffer containing protease inhibitor cocktail (SIGMA)
and phosphatase inhibitors (Roche). The tissue was dissociated using a tissue
homogenizator, incubated for 10min on ice and then cleared by centrifugation.
Alternatively, proteins were isolated in parallel to DNA and RNA using TRIzol
Reagent according to the manufacturer’s protocol (Invitrogen). Epidermal
lysates were prepared from newborn and adult epidermis. Newborn epidermis
was separated from the dermis after floating back-skin on ice-cold 0.5 M
ammonium thiocyanate/PBS for 20 min, and adult epidermis was mechani-
cally scraped-off the dermis. The epidermis was subsequently minced and
proteins were isolated using TRIzol Reagent.
The use of human specimen involved in this study was approved by the insti-
tutional review board at the Medical Faculty of the University of Cologne.
Written informed consent was obtained from patients in accordance with insti-
tutional review board policies and procedures for research dealing with tumor
specimen.
Apoptosis in Mouse Epidermis
DMBA (25 ug) or TPA (104M) or both were applied to the backs of six mice
of each genotype, and mice were killed 24 hr later. Apoptotic cells in skin
biopsy specimen were detected by immunohistochemistry against cleaved
caspase-3. The number of positively stained cells within the epidermis was
evaluated per millimeter of basement membrane using phase-contrast
microscopy of at least 60 nonserial tissue sections and subsequent image
analysis (Aperio, Slidepath).
Cell Proliferation in Mouse Epidermis
Control and Par3 cKO littermates (n = 6 each) were treated with TPA alone
(104 M), DMBA alone (25 mg) for 24 hr, or were treated with DMBA and subse-
quently treated with two doses of TPA over 7 days. At the end of the experi-
ment, mice were injected intraperitoneally with BrdU (Sigma) at 50 mg/kg,
and killed 3 hr later. Using an anti-BrdU antibody (DAKO), the number of
BrdU-stained cells within the epidermis was evaluated per millimeter of base-
ment membrane using phase-contrast microscopy of at least 30 nonserial
tissue sections and subsequent image analysis (Aperio and Slidepath).c.
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out for net proliferation.
Antibodies
The following antibodies were used in this study: rabbit polyclonal antibodies
directed against Par3 aa712-936 (Iden et al., 2006) and commercial sources
(Millipore/Upstate, no. 07-330, and SIGMA-Aldrich HPA030443), aPKCzeta
(C-20, Santa Cruz), PARP (no. 9542), phospho-p42/44 (Cell Signaling, no.
4370), pAkt Ser473 (Cell Signaling, no. 4060), ZO-1 (no. 61-7300, Invitrogen),
cleaved caspase-3 (Cell Signaling, no. 9661), mouse-specific caspase 9
(Cell Signaling no. 9504), cyclin D1 (Upstate no. 05-815), Tiam1 (C-16, Santa
Cruz), Keratin-1 (Covance, PRB149P), Tom20 (Santa Cruz, no. sc-11415),
murine Bax (BD PharMingen, no. 554106), HA-tag (Y-11, Santa Cruz, no.
sc-805), pcRAF Ser338 (Cell Signaling, no. 9427), Sos2 (Santa Cruz, no. sc-
258), mouse monoclonal antibodies against ZO-1 (Invitrogen, no. 33-9100),
Ras (BD Transduction, no. R02120), Ras (Ab-3, Millipore, no. OP-40), Rac1
(Upstate, clone 23A8, no. 05-389), ERK2 (BD Transduction, no. 610103),
a-tubulin (SIGMA-Aldrich, no. T-5168, clone B-5-1-2), BrdU (DakoCytomation,
no. MO744), E-cadherin (no. 610181, BD Transduction), b-catenin (BD Trans-
duction, no. 610154), active Bax (clone 6A7, BD Pharmingen no. 556467),
aPKCzeta (H-1, Santa Cruz, no. sc-17781), aPKCl/i (BD Transduction Labs,
no. P20520, clone 23), HA-tag (12CA5, own hybridoma), HA-probe (F-7, Santa
Cruz, no. sc-7392). For secondary detection, species-directed antibodies
conjugated with AlexaFluor fluorophors (Molecular Probes) or horse radish
peroxidase (GE Healthcare) were used for immunofluorescence or western
blot studies, respectively.
Isolation of Primary Mouse Keratinocytes
Primarymurine keratinocytes were isolated from newbornPar3flox/floxmice and
cultured as previously described (Mertens et al., 2005), whereby epidermal
and dermal fractions were kept separate. Primary and SV40-immortalized
epidermal and dermal cells expressing typical keratinocyte marker proteins
have been used in this study. Cells were plated on Collagen I-coated dishes
and used up to passage 20. Par3 was deleted by retroviral infection with
self-excising Cre recombinase (Silver and Livingston, 2001). Corresponding
parental cell isolations of identical passage served as control.
Tumor Promoter Treatments In Vitro
Keratinocytes were growth factor-starved for 2 hr, and then treated with either
40 ng/ml murine epidermal growth factor (BD Biosciences) or 0.68 mM TPA
(SIGMA-Aldrich) for indicated time points. Lysates of adherent and floating
cells were combined for subsequent biochemical analysis.
Colony Formation Assays
Cold growth factor-reduced matrigel (BD Biosciences) was diluted 1:1 in ker-
atinocyte culture medium and 30 ml were pipetted into a chilled 96 well plate.
Subconfluent keratinocytes were harvested by trypsinization, counted and
seeded into a matrigel matrix to yield a final concentration of 53 103 cells/ml.
The matrigel:cell mix was incubated at 37C for 45 min to solidify the matrigel.
Afterward, culture medium was added to the top and replaced every second
day. Colony formation was followed over a period of up to 3 weeks.
Immunofluorescence Analysis: Mono- and Multilayer Tissue
For monolayer cultures, keratinocytes were seeded on Collagen I-coated 8
well or 16 well LabTek Chamber Slides (Nunc), grown until confluency and
then switched to NC levels (2mM). For analysis of multilayer cultures, keratino-
cytes were seeded on Collagen I-coated TransWell Filters (TransWell Clear,
0.4 mmpore size, 6.5 mm diameter, Nunc), grown to confluency and then incu-
bated at NC levels for several days. For immunofluorescence staining, mono-
layer and multilayer cultures were washed twice with PBS and fixed with either
PFA (4% PFA in PBS 10 min at room temperature, followed by 15 min 0.5%
Triton X-100 in PBS for permeabilization) or ethanol/acetone (30 min 96%
ethanol on ice, followed by 3 min incubation of ice-cold acetone at RT). Cells
were blocked with 5% BSA for 1 hr at RT, and subsequently incubated with
primary antibodies diluted in AB buffer (10 mM Tris-HCl, 150 mM NaCl, and
0.1% BSA) in a humidified chamber overnight at 4C. Incubation with Alexa-
Fluor 488- and 568-conjugated secondary antibodies (Invitrogen) and TOPRO
as nuclei stain (Invitrogen) was carried out for 1 hr at room temperature in ABCanbuffer. Immunostained cells on chamber slides weremounted inMowiol; filters
with multilayer cultures were first excised and then mounted to a glass slide.
Additional experimental procedures can be found in Supplemental Experi-
mental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, one table, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.ccr.2012.08.004.
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